Tempus AI Inc. reported third quarter 2025 revenue of $334.2 million, an increase of 84.7% from the same period in 2024. Gross profit rose 98.4% year-over-year to $209.9 million. The company reported a net loss of $80.0 million, compared to a net loss of $75.8 million in the third quarter of 2024. Genomics revenue reached $252.9 million, up 117.2% year-over-year. Tempus delivered 217,000 clinical tests in the quarter, representing 33% growth, with oncology and hereditary test volumes increasing by 27% and 37%, respectively. Insights bookings totaled $150 million, up 37.6% year-over-year. The company raised its full-year 2025 revenue guidance to $1.27 billion, indicating about 80% growth. Tempus ended the quarter with $764.3 million in cash and marketable securities. Business developments included expanding collaboration with Northwestern Medicine to integrate its generative-AI clinical co-pilot, acquiring Paige to strengthen digital pathology capabilities, and receiving FDA 510(k) clearances for RNA NGS and cardiac imaging platforms.